Proximagen Neuroscience plc is aiming to raise £50 million (US$80 million) through the placement of 35.7 million shares, in what the firm said is one of the largest UK biotech financings in the past decade. (BioWorld Today)

Another runner has stumbled on a regulatory hurdle on the race to get the first acute hereditary angioedema (HAE) drug to market. (BioWorld Today)

With the first Phase I data and the first patents relating to deuterium-modified compounds firmly in hand, Concert Pharmaceuticals Inc. set out looking for a partner and ended up scoring big by signing GlaxoSmithKline plc to a multiproduct collaboration that could be worth more than $1 billion in up-front and milestone payments. (BioWorld Today)